Clinical outcomes with the combination of encorafenib, binimetinib, and cetuximab exceed historic data in patients with BRAF V600E-mutant metastatic colorectal cancer.
For all the positive data associated with PARP inhibitors in patients with epithelial ovarian cancer who have known BRCA mutations and despite several agents winning FDA approval over the past few years, PARP inhibitors aren’t curing patients.
The oral multi-kinase inhibitor regorafenib extended progression-free survival in patients with metastatic or unresectable biliary tract cancer who were previously treated with gemcitabine and a platinum-based chemotherapy.
Shannon Westin, MD, discusses the evolving role of PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.
The combination of dabrafenib and trametinib induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.
The novel oral anticancer regimen known as SM-88, which consists of a tyrosine derivative, an mTOR inhibitor, a CYP3a4 inducer, and an oxidative stress catalyst, has promising efficacy with no meaningful toxicity in patients with metastatic pancreatic cancer who have progressed on at least 1 prior line of therapy.
Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.
The prognosis for women with recurrent or metastatic cervical cancer after treatment failure is notoriously poor, but immunotherapy agents may offer longer survival for this population.
Overall survival in metastatic gastric/gastroesophageal junction cancer improved significantly in patients who received the combination therapy TAS-102, irrespective of prior gastrectomy.
The FDA has granted an approval to SB3 (Ontruzant; trastuzumab-dttb), a trastuzumab biosimilar, for the treatment of patients with HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma.